Target Name: GZMM
NCBI ID: G3004
Review Report on GZMM Target / Biomarker Content of Review Report on GZMM Target / Biomarker
GZMM
Other Name(s): LMET1 | natural killer cell granular protease | lymphocyte met-ase 1 | MET1 | met-ase | Granzyme M, transcript variant 1 | GZMM variant 1 | Lymphocyte met-ase 1 | GRAM_HUMAN | Natural killer cell granular protease | Met-ase | Granzyme M | Met-1 serine protease | granzyme M | Hu-Met-1 | HU-Met-1 | Granzyme M (isoform 1)

GZMM: A Drug Target / Disease Biomarker

GZMM, or G protein-coupled receptor (GPCR), is a protein that is expressed in many tissues throughout the body and plays a crucial role in cellular signaling. GPCRs are a family of transmembrane proteins that are involved in a wide range of physiological processes, including sensory perception, neurotransmission, and hormone signaling. They are one of the most widely studied protein families in the human proteome and are known for their ability to interact with a wide variety of ligands, including drugs. As a result, GPCRs have become a focus of interest for drug development in recent years.

GZMM is a type of GPCR that is expressed in the brain and is involved in the regulation of a wide range of physiological processes, including mood, anxiety, and learning. It is characterized by a long extracellular loop (ECL) and a short intracellular loop (ICL), and has been shown to play a role in the regulation of neurotransmitter release from neurons. GZMM is also involved in the regulation of ion channels, which are critical for the rapid and delayed responses of neurons.

GZMM is a druggable protein target because of its unique structure and the various functions that it is involved in. Its ECL is known to be a potential drug binding site, and several small molecules have been shown to interact with GZMM in cell culture assays. Additionally, GZMM has been shown to play a role in the regulation of neural plasticity, which is the ability of the brain to change and adapt over time. This suggests that GZMM may be a useful target for the development of drugs that enhance or protect neural plasticity.

GZMM is also of interest as a potential biomarker for various psychiatric and neurological disorders. The regulation of GZMM has been implicated in the development and progression of a wide range of psychiatric and neurological disorders, including depression, anxiety, and schizophrenia. Additionally, changes in GZMM expression have been observed in the brains of individuals with neurodegenerative disorders, which suggests that GZMM may be a useful biomarker for these conditions.

Despite the potential benefits of GZMM as a drug target and biomarker, much more research is needed to fully understand its role in cellular signaling and its potential therapeutic uses. One of the major challenges in studying GZMM is its complex structure, which makes it difficult to study in detail. Additionally, the high number of potential drug targets for GZMM makes it difficult to identify small molecules that are likely to be effective in cell culture assays.

In conclusion, GZMM is a protein that is of interest as a drug target and biomarker due to its unique structure and the various functions that it is involved in. Its ECL is known to be a potential drug binding site, and several small molecules have been shown to interact with GZMM in cell culture assays. Additionally, GZMM has been shown to play a role in the regulation of neural plasticity, which suggests that it may be a useful target for the development of drugs that enhance or protect neural plasticity. Further research is needed to fully understand the role of GZMM in cellular signaling and its potential therapeutic uses.

Protein Name: Granzyme M

Functions: Cleaves peptide substrates after methionine, leucine, and norleucine. Physiological substrates include EZR, alpha-tubulins and the apoptosis inhibitor BIRC5/Survivin. Promotes caspase activation and subsequent apoptosis of target cells

The "GZMM Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about GZMM comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

H1-0 | H1-1 | H1-10 | H1-10-AS1 | H1-2 | H1-3 | H1-4 | H1-5 | H1-6 | H1-7 | H1-8 | H1-9P | H19 | H19-ICR | H2AB1 | H2AB2 | H2AB3 | H2AC1 | H2AC11 | H2AC12 | H2AC13 | H2AC14 | H2AC15 | H2AC16 | H2AC17 | H2AC18 | H2AC20 | H2AC21 | H2AC25 | H2AC3P | H2AC4 | H2AC6 | H2AC7 | H2AJ | H2AP | H2AX | H2AZ1 | H2AZ1-DT | H2AZ2 | H2AZ2-DT | H2AZP2 | H2BC1 | H2BC10 | H2BC11 | H2BC12 | H2BC12L | H2BC13 | H2BC14 | H2BC15 | H2BC17 | H2BC18 | H2BC20P | H2BC21 | H2BC26 | H2BC27P | H2BC3 | H2BC4 | H2BC5 | H2BC6 | H2BC7 | H2BC8 | H2BC9 | H2BP1 | H2BP2 | H2BP3 | H2BW1 | H2BW2 | H2BW4P | H3-3A | H3-3B | H3-4 | H3-5 | H3-7 | H3C1 | H3C10 | H3C11 | H3C12 | H3C13 | H3C14 | H3C15 | H3C2 | H3C3 | H3C4 | H3C6 | H3C7 | H3C8 | H3P16 | H3P36 | H3P37 | H3P44 | H3P5 | H3P6 | H4C1 | H4C11 | H4C12 | H4C13 | H4C14 | H4C15 | H4C16 | H4C2